Catalog Advanced Search
165 Results
-
Includes a Live Web Event on 12/19/2023 at 11:00 AM (PST)
Content provided by InflaRX (No CE credits offered)
Webinar Description:
This sponsored webinar will provide an overview of the Complement System and C5a Activation, the potential role of C5a in COVID-19 disease progression, and a review of the clinical data for a product recently FDA-authorized for emergency use in critically ill adult patients hospitalized with COVID-19.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by InflaRX for this sponsored webinar.
Niels Riedemann, MD, PhD
Chief Executive Officer and Founder
InflaRX
Niels Riedemann, MD, PhD, is a co-founder and CEO of InflaRx. He has over 15 years of experience in biotech and 23 years of experience in complement immunology research, with more than 60 peer-reviewed scientific publications in highly ranked journals and several national and international accolades for his research and work. From 2009 to 2015, he served as Vice Director of Intensive Care Medicine at Friedrich Schiller University in Jena, Germany, where he led a 50-bed academic ICU unit. He received his medical training from Albert Ludwig University and Stanford University, worked as postdoctoral research fellow at the University of Michigan, and received his PhD. from Hannover Medical School. He is board certified general surgeon and intensive care physician. Dr. Riedemann serves as Co-Chair of the Health Politics working group of Bio-Deutschland and as a member of the board of trustees for the German Sepsis Foundation.
-
Includes a Live Web Event on 12/14/2023 at 9:00 AM (PST)
This live virtual event, scheduled for December 14, 2023, will cover critical topics related to HAIs, offering attendees the latest clinical knowledge and updated recommendations for timely infection prevention and treatment
Description:
Date: December 14, 2023
Time: 12:00 - 3:30 pm ET / 9:00 am - 12:30 pm PT
Healthcare-associated infections (HAIs) are the most common complication associated with hospital care and continue to be a significant concern for critical care professionals. Centers for Disease Control and Prevention (CDC) reports that one in every 31 hospital patients acquires at least one HAI each day, costing billions for healthcare organizations. The potential for HAIs to lead to sepsis further emphasizes the need for HAI prevention measures, which also serve as sepsis prevention strategies.
It is imperative for healthcare professionals to direct their focus towards identifying and capitalizing on opportunities for improving performance and outcomes across various departments and specialties related to HAIs and the prevention of infections that can lead to sepsis.
To address this pressing issue, Sepsis Alliance is hosting the 2023 Sepsis Alliance Symposium: Healthcare-Associated Infection. This live virtual event, scheduled for December 14, 2023, will cover critical topics related to HAIs, offering attendees the latest clinical knowledge and updated recommendations for timely infection prevention and treatment. The aim of this half-day event is to establish the importance of HAI mitigation within clinical practices and enhance the overall clinical outcomes for patients affected by HAIs and sepsis.
Topics covered will include:
- Healthcare-associated infection prevention priorities (CAUTIs, CLABSIs, VAEs, CDIFF, SSIs);
- The Impact of MDROs including Candida Auris on HAIs; Skin and Skin Structure Infections (SSIs, Cellulitis, and HAPIs);
- HAI risks and considerations in immunocompromised patients.
This event is FREE for registrants and will offer CE contact hours for nurses.
Learning Objectives:
At the end of the activity, the learner should be able to:
- Demonstrate increased knowledge relating to maintaining a compliant and effective infection prevention and control program in the healthcare setting;
- Describe examples of infection prevention and control evidence-based best practices and recommendations;
- Propose innovative approaches, protocols, tools and documentation for limiting healthcare-associated infections.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Symposium Supporters:
This activity is supported through an Independent Medical Education grant from Merck & Co. Inc.
Sepsis Alliance gratefully acknowledges the support provided for this event by Seres Therapeutics.
Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA (Moderator)
Infection Control Officer
Jefferson Health, New Jersey
Cindy Hou, DO, MA, MBA, CIC, CPHQ, FACOI, FACP, FIDSA, is the Infection Control Officer and Medical Director of Research for Jefferson Health - New Jersey (JNJ) and an infectious diseases specialist. She is dually board certified in internal medicine and infectious diseases. Dr. Hou has expertise in sepsis, antibiotic stewardship, and infection control. Dr. Hou is the Chief Medical Officer of Sepsis Alliance and a member of its board of directors; she is also a medical advisor for the Sepsis Innovation Collaborative. Dr. Hou earned an M.B.A. and M.A. from Boston University, a D.O. from the University of New England College of Osteopathic Medicine, and a BS from Yale University. She has a certification in Infection Prevention and Control (CIC), is a Certified Professional in Healthcare Quality (CPHQ), and a Certified Professional in Patient Safety (CPPS). Dr. Hou is a fellow for the American College of Osteopathic Internists (ACOI), American College of Physicians (ACP) and the Infectious Diseases Society of America (IDSA).
No relevant financial relationships to disclose.
J. Hudson Garrett Jr., Ph.D., MPH, MBA, CPPS, FACHE, FSHEA, FNAP, FIDSA
Adjunct Assistant Professor of Medicine, Division of Infectious Diseases, Department of Medicine
University of Louisville School of Medicine
John Hudson Garrett Jr., Ph.D., MPH, MBA, CPPS, FACHE, FSHEA, FNAP, FIDSA is a driven, results-oriented, and collaborative healthcare and medical executive with a proven track record of growing clinical and medical affairs strategies across a broad variety of targets including both inpatient and outpatient healthcare settings, as well as community settings. Dr. Garrett has a passion for positively impacting patient safety through meaningful collaboration with patients, regulators, accreditation bodies, healthcare professionals, clinical organizations, industry partners, and integrated healthcare delivery networks. Dr. Garrett’s specific focus has been on the prevention of healthcare-associated and community-associated infection prevention and control, and he believes in advancing global evidence-based practices to reduce healthcare-associated infections, improve patient satisfaction and occupational safety, reduce costs, and improve overall healthcare outcomes.
Catherine Liu, MD
Professor, Vaccine and Infectious Diseases Division
Fred Hutchinson Cancer Center
Catherine Liu, MD is an infectious diseases physician and professor in the Vaccine and Infectious Diseases Division at Fred Hutchinson Cancer Center (FHCC) and in the Division of Allergy and Infectious Diseases at University of Washington. She serves as the Director of the Antimicrobial Stewardship and Outpatient Parenteral Antimicrobial Therapy (OPAT) Programs and Associate Director of Infection Prevention at FHCC. Her clinical and research interests focus on the implementation and evaluation of strategies to optimize antimicrobial use and infectious disease management in immunocompromised hosts with a focus on patients with cancer and hematopoietic cell transplant recipients.
Melissa Miller, MD, MS, FCCM
Medical Officer, Division of Healthcare-Associated Infections in the Center for Quality Improvement and Patient Safety
Agency for Healthcare Research and Quality (AHRQ)
Melissa Miller, MD, MS, FCCM, serves as Medical Officer with the Division of Healthcare-Associated Infections in the Center for Quality Improvement and Patient Safety at the Agency for Healthcare Research and Quality (AHRQ). Dr. Miller is the Project Officer for the AHRQ Safety Program for MRSA Prevention. She was previously the Project Officer of the AHRQ Safety Program for Improving Antibiotic Use, which promoted antibiotic stewardship activities in multiple healthcare settings, and for the AHRQ Safety Program for ICUs: Preventing CLABSI and CAUTI. She represents AHRQ on the Presidential Advisory Committee on Combating Antibiotic-Resistant Bacteria (PACCARB) and as an ex-officio member of CDC’s Healthcare Infection Control Practices Advisory Committee (HICPAC). She has training in internal medicine, infectious diseases, pulmonary medicine, and critical care medicine, and has a background as a critical care nurse. Prior to joining AHRQ, she held the position of Assistant Professor at the University of Michigan and Medical Director of the Medical Intensive Care Unit at the Ann Arbor VA Medical Center, and conducted research on the implementation of evidence-based multidisciplinary ICU interventions.
Frank A. Scannapieco, DMD, PhD
Chair and SUNY Distinguished Professor of Oral Biology, Associate Dean for Faculty and Professional Development
University at Buffalo School of Dental Medicine
Frank Scannapieco, D.M.D., Ph.D. is a State University of New York (SUNY) Distinguished Professor of Oral Biology and has an international reputation in oral biology. His research interests have included studies of basic dental plaque (biofilm) formation mechanisms and implications for health and disease. His laboratory has studied the interaction between salivary proteins and bacteria, and how these influence oral biofilms. He is also a pioneer in studies connecting oral and systemic diseases such as pneumonia, COPD, diabetes, and cancer.
A member of the University at Buffalo faculty since 1991. Dr Scannapieco served as the Chair of the Department of Oral Biology from 2004 to 2022. Over his career, he has mentored numerous junior faculty, postdoctoral fellows, and graduate, dental, and college students. He was awarded several research grants over his career, edited several books and journal supplements, and has published over 170 peer-reviewed articles and book chapters.
A fellow of the American Association of Dental Research, Scannapieco has received several awards, including the SUNY Chancellor’s Award for Excellence in Scholarship and Creative Activities, Distinguished Scientist Award in Oral Biology from the International Association for Dental Research, the William J. Gies Award for Achievement from the American Dental Education Association, and the Irwin D. Mandel Distinguished Mentoring Award, from the American Association for Dental Research.
He received a bachelor’s degree in biology and doctorate in dental medicine from the University of Connecticut, a master’s degree in biology from Northeastern University, and a PhD in oral biology and certificate in periodontics from the University at Buffalo.
Nasia Safdar, MD, Ph.D
Professor in Division of Infectious Disease
University of Wisconsin School of Medicine and Public Health
Nasia Safdar, MD, Ph.D,is a professor in the Division of Infectious Disease within the Department of Medicine at the University of Wisconsin School of Medicine and Public Health, where she is s also Associate Dean for Clinical Trials and Research Director of the Wisconsin Medicine Institute for Clinical Trials. Dr. Safdar is also Faculty Director of Investigator-Initiated and Multisite Research, Institute for Clinical and Translational Research. Dr. Safdar serves as the Associate Chief of Staff for Research at the William S. Middleton Veterans Hospital and as the Medical Director of Infection Control at UW Health. Her research, which has been funded by VA, AHRQ, PCORI, and NIH, aims to reduce and prevent healthcare-associated infections by identifying, testing, and implementing novel interventions.
Because of her work and research in this area, in 2017, Dr. Safdar received a President’s Early Career Award for Scientists and Engineers (PECASE), the highest honor bestowed by the U.S. government on outstanding scientists and engineers beginning their independent careers. In 2018, she received the NIH Director’s New Innovator Award. In 2019, she received the Oswald Avery Award for Early Achievement which honors ISDA fellows aged 45 or younger for overall outstanding achievements in infectious disease. In 2021, Dr. Safdar became an invited fellow of the Alpha Omega Alpha Honor Medical Society.
Charles Holland
President and Chief Executive Officer
St. Bernard Hospital
Charles Holland is President and Chief Executive Officer of St. Bernard Hospital, a safety-net community hospital that has served the Englewood community and Chicago’s South Side for nearly 120 years. He joined the hospital in 1998, assuming his current leadership position on January 1, 2013. He is a member of the hospital’s Board of Trustees.
Mr. Holland has been instrumental in advancing the stature of the hospital as a community leader. His focus is on programs to keep people well and help prevent disease. In 2016, the hospital opened a 70,000 square foot state of the art Ambulatory Care Center to offer comprehensive outpatient services. Also, he led the work on the hospital’s affordable housing project, establishment of the St. Bernard Hospital Dental Center and the Pediatric Mobile Health Unit program, which has delivered 20 years of service.
Under Mr. Holland’s leadership, the hospital significantly and swiftly improved its patient safety ratings, and it has attracted critical donations of improved technology to advance patient care. An unwavering advocate for health equity, Mr. Holland is president of the board of the Center for Better Aging, and he is also a board member of the South Side Healthy Community Organization.
Agenda
December 14, 2023
Time (ET) Session Title Presenter 12:00-12:05 Welcome and Opening Remarks Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA
Jefferson Health - East Region12:05-12:35 Using Leapfrog’s Hospital Survey as a Safety Roadmap to Improve Hand Hygiene and Reduce HAIs Charles Holland
St. Bernard Hospital
Michael Richardson, MHSc, BSN, RN, CPPS, CPHRM
St. Bernard Hospital12:35-1:05 Prevention of Healthcare-Associated Infections and Sepsis in Immunocompromised Hosts Catherine Liu, MD
Fred Hutchinson Cancer Center1:05 - 1:35 AHRQ’s Healthcare-Associated Infections (HAI) Program: Research to Implementation Melissa Miller, MD, MS, FCCM
Agency for Healthcare Research and Quality (AHRQ)1:35 - 1:50 Sponsor Innovation Lunch & Learn: Seres Therapeutics (More information coming soon) 1:50-2:20 Healthcare-Acquired Infections and Sepsis: The Role of Infection Control and Environmental Management Nasia Safdar, MD, Ph.D
University of Wisconsin School of Medicine and Public Health2:20-2:50 The Role of Oral Biofilms and Periodontal Disease in Ventilator and Non-ventilator Associated Events Frank Scannapieco, D.M.D., Ph.D
University at Buffalo School of Dental Medicine2:50-3:20 Sepsis, Healthcare-Associated Infection, and Patient Safety: Strategies for Interprofessional Prevention and Improvement
J. Hudson Garrett Jr., Ph.D., MSN, MPH, MBA, FNP-BC, IP-BC, PLNC, CFER, AS-BC, VA-BC, HACP-IC, CMRP, LTC-CIP, CIC, DICO-C, CPPS, CPHQ, CVAHP, CPXP, CDIPC, CPHRM, FACDONA, FAAPM, FACHDM, FNAP, FAHVAP, FACHE, FSHEA, FIDSA
University of Louisville School of Medicine3:20-3:30 Closing Remarks Cindy Hou DO, MA, MBA, FACOI, FACP, FIDSA
Jefferson Health - East RegionProvider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 3.6 contact hours.
Other healthcare professionals will receive a certificate of attendance for 3 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
-
Live webinar about the nurse’s role and responsibility in AMR and AMS
Description:
A multidisciplinary approach is needed to implement an effective antimicrobial stewardship (AMS) program. Traditionally, nurses have been excluded from the AMS team structure. However, to steer a successful program in the increasingly complex field of health care, it is crucial to involve dedicated nurses and nursing professionals. The role of nurses in caring for and improving outcomes for patients with infections and sepsis is well known. Nurses can also directly impact antimicrobial resistance (AMR) and antimicrobial stewardship (AMS) through a variety of nurse-driven protocols and practices. These can include assessments and allergy documentation, evidence-based specimen collection techniques, consideration for antimicrobial duration and route of administration, and thoughtfulness in culturing. In this presentation, attendees will learn about the nurse’s role and responsibility in AMR and AMS, gain an understanding of opportunities for and barriers to nurses’ engagement in AMS across the continuum of care, and examine key strategies to empower nurses’ ownership, accountability, and contribution to the core elements of AMS.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Webinar Supporter:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by Roche.
May M. Riley, MSN, MPH, RN, ACNP, CCRN, CIC, FAPIC
Infection Control Consultant
Stanford Health Care
May Riley, MSN, MPH, RN,ACNP, CCRN, CIC, FAPIC is an Infection Control Consultant at Stanford Health Care. May has been practicing in the field of infection control and hospital epidemiology since 2005. She has extensive nursing experience including medical/surgical, neurosurgery, trauma, liver transplant, and critical care nursing. May holds two master degrees, an MSN from the UCLA School of Nursing in acute care, and an MPH in Epidemiology from the UCLA School of Public Health. She will start her doctor of nursing practice study in August.
May has numerous publications on infection prevention and infectious disease control. May served on the ANA/CDC Work Group for Engaging Nurses in Antibiotic Stewardship as a subject matter expert to contribute her expertise in developing the ANA/CDC White Paper defining the nurse’s role in stewardship. Additionally, May collaborated with APIC to conduct a leadership interview. She interviewed the founders and pioneers in the ANA/CDC Work Group for Engaging Nurses in Antibiotic Stewardship. To trumpet the vision and mission of engaging nurses to antibiotic stewardship, May published the leadership interview article in one of the APIC flagship journals ̶ Prevention Strategist in 2016.
May is also a Consulting Editor for Journal of “Critical Care Nursing Clinics of North America” in Elsevier. -
Live CE webinar regarding the inclusion of the SEP-1 bundle in the Hospital Value-Based Purchasing (VBP) program
Description:
Date: October 10, 2023
Time: 3:00 - 4:00 pm ET
The Centers for Medicare and Medicaid Services (CMS) recently finalized the inclusion of the Severe Sepsis and Septic Shock Management Bundle (SEP-1) in the Hospital Value-Based Purchasing (VBP) program as part of the fiscal year 2024 Hospital Inpatient Prospective Payment System (IPPS). SEP-1 has been a part of the Hospital Inpatient Quality Reporting Program since fiscal year 2017. Research on the SEP-1 bundle showed compliance improved outcomes and lowered mortality from 27% to 22%. With the new addition to the VBP program, hospitals are now incentivized to improve sepsis care by not only requiring them to report on their sepsis care but to meet standards for how often they comply. A hospital’s VBP total performance score (TPS) is based on performance, as compared to their peers, and determines whether they receive full payment or not.
During this webinar attendees will receive an overview of the key components of the SEP-1 measure and the Hospital VBP program. Learners will also delve into the implications of SEP-1 addition to VBP and making it a pay-for-performance measure versus a pay-for-participation measure and what this means for them organizationally. Lastly, strategies on how to analyse and improve organizational SEP-1 compliance and maximize VBP total performance score (TPS) will be discussed.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Webinar Supporter:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by the Sepsis Alliance Institute sponsors.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.2 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.0 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
-
Annual virtual conference designed to explore an array of sepsis-related topics in healthcare.
Description
This September, Sepsis Alliance is proudly hosting its Sepsis Alliance Summit. Set to coincide with Sepsis Awareness Month, the event will feature two days of learning and inspiration for healthcare professionals across the continuum of care, including nurses, physicians, pharmacists, allied health professionals, data/quality/safety/IT professionals, students, leadership, policy makers, and industry leaders.
Designed to explore an array of sepsis-related topics in healthcare, the Sepsis Alliance Summit will include expert presentations from clinicians, innovation experts, and other influential leaders. Join the sessions that are relevant to your practice and interests, and increase your sepsis knowledge and skills. We encourage you to attend sessions live, as speakers will be present to answer questions and share knowledge for most sessions. If you are unable to attend live, sessions will be prerecorded and available at a later time.
FREE Nursing CE Credits Offered!
Continuing nursing education credits will be available, as will post-event access to resources, ideas, and innovations to improve sepsis care. Sepsis Alliance is a Provider approved by the California Board of Registered Nursing for 9.0 contact hours, Provider Number CEP17068.
Other healthcare providers will receive a certificate of attendance.
Sepsis Alliance is proud to offer the Sepsis Summit at no charge to participants. Please consider making a donation to help Sepsis Alliance continue to educate thousands of healthcare professionals and members of the public every year. Click here to donate.
Agenda
September 27, 2023
September 28, 2023
-
Recorded On: 08/31/2023
Content provided by Beckman Coulter (No CE credits offered)
Webinar Description:
In this sponsored webinar, Tobin Efferen, MD, MS, will explore the development of machine learning models in the prediction and diagnosis of sepsis. Dr. Efferen will review some of his own research around the inclusion of biomarkers in AI models and share information on potential future products.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by Beckman Coulter for this sponsored webinar.
Tobin Efferen, MD, MS
Medical Director, Medical and Scientific Affairs
Beckman Coulter
Tobin Efferen, MD, MS, has practiced emergency medicine on the south and west side of Chicago for the last 15 years. Initially interested in marine biology, Dr. Efferen switched gears after a brief stint at the New England Aquarium in Boston. As a laboratory technician at a biotech startup in Connecticut, he performed both basic and translation biobehavioral research on novel antipsychotic compounds. After receiving a master’s degree in Neurobehavioral Biology from NYU, he continued on to the NYU School of Medicine for his MD. He went on to complete a residency in emergency medicine at the University of Chicago. After graduating he stayed on at Mount Sinai Hospital as an attending, covering both Holy Cross Hospital and Mount Sinai Hospital in the Sinai Health System. As the Assistant Medical Director for the Emergency Department, Dr. Efferen oversaw the quality program and was the Director of the clerkship in emergency medicine for six physician assistant programs in the Chicagoland area.
He now works part time in the ED and full time as a Medical Director on the Medical/Scientific Affairs team for Beckman Coulter. His work there is focused on the scouting of novel biomarkers to improve the identification and evaluation of complex disease states such as dysregulated host response and acute kidney injury. Another area of focus is the development and implementation of machine learning-based algorithms for use in the emergent and critical care settings.
-
Recorded On: 08/24/2023
Gain invaluable insights to enhance prehospital practices and ultimately improve patient survival rates and outcomes.
Description:
The profound impact and implications of several recently published papers have reshaped our understanding of prehospital alerts, antibiotics, and fluid administration. Drawing from this cutting-edge research and innovative methodologies, attendees will explore the transformative effects of prehospital alerts on emergency medical services (EMS) and the subsequent improvements in patient outcomes. The intricacies of alerts, clinical decision-making, and resource allocation will be highlighted, in addition to the importance of accurate and timely information in prehospital care. Antibiotic administration in prehospital settings, the latest evidence on fluid administration, and the potential benefits, risks, and controversies of this crucial intervention will also be examined. By synthesizing these recent updates, this presentation aims to equip healthcare professionals with invaluable insights to enhance prehospital practices and ultimately improve patient survival rates and outcomes.
Learning Objectives:
At the end of the activity, the learner should be able to:
- Analyze the implications of updates on prehospital alerts, antibiotics, and fluid administration;
- Evaluate the relationship between prehospital alerts and clinical decision-making;
- Apply knowledge gained to assess the potential benefits and challenges associated with alerts in EMS;
- List proposed effective strategies for antibiotic administration and fluid management in prehospital care based on recent research.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Webinar Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by the Sepsis Alliance Institute sponsors.
Rommie L. Duckworth, MPA, LP, EFO, FO
Captain, EMS Coordinator
Ridgefield (CT) Fire Department
Rom Duckworth, MPA, LP, EFO, FO, is a dedicated emergency responder, author, and educator with more than thirty years of experience working in career and volunteer fire departments, hospital healthcare systems, and private emergency medical services. Rom is currently a career fire Captain and paramedic EMS Coordinator for Ridgefield (CT) Fire Department and Founder of the New England Center for Rescue and Emergency Medicine. Rom is the recipient of the American Red Cross Hero award, Sepsis Alliance Sepsis Hero award, the EMS 10 Innovators award, and the NAEMT Presidential award. An Advisory Board member for the Sepsis Alliance, Rom is the co-author of the Sepsis Care chapter in the NAEMT Advanced Medical Life Support (AMLS) program as well as chapters in more than a dozen EMS, fire, rescue, and medical textbooks and over 100 published articles in fire and EMS journals, magazines, and websites. Rom is an international advocate and leader in emergency services education.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 1.7 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.25 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
-
Recorded On: 07/27/2023
Recorded peer-to-peer roundtable discussion on innovative approaches, protocols, tools, and documentation practice which have improved sepsis management and care at panelists' organizations.
Description:
In this peer-to-peer roundtable discussion, sepsis coordinators and specialists will discuss the innovative approaches, protocols, tools, and documentation practice which have improved sepsis management and care at their organizations. Our panelists represent a variety of care situations from critical access hospitals to larger academic centers.
Panelists will share what has worked at their institutions, ranging from critical access hospitals to larger academic centers, as well as areas where they still struggle and the adjustments, they’ve made to improve outcomes and meet requirements. Topics of discussion will include documentation, promoting buy-in and physician support for a sepsis program, and the evolution of fluid resuscitation.Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Learning Objectives:
At the end of this activity, the learner should be able to:
- Explain different care situations and challenges faced by sepsis coordinators or healthcare professionals managing sepsis;
- Summarize the areas where sepsis coordinators and specialists struggle in sepsis management and care, and identify the adjustments made to improve outcomes and meet requirements;
- Describe the importance of documentation in sepsis management and care;
- Analyze the evolution of fluid resuscitation in sepsis management, including its historical context and the current best practices.
Webinar Supporters:
Sepsis Alliance gratefully acknowledges the support provided for this webinar by the Sepsis Alliance Institute sponsors.
Michelle Evans, RN, MSN, NP-C
Sepsis Program Coordinator
Summa Health System
Michelle Evans, RN, MSN, NP-C, obtained her associate's degree in nursing in 1999 and her bachelor of science in nursing in 2007, both from Walsh University. She earned her master's in advanced practice nursing in 2010 from Malone University and is board-certified through the ANCC as a family nurse practitioner. Her clinical background is critical care/rapid response and hospitalist medicine. She carried her CCRN Certification through the AACN from 2005 - 2017, and is trained in fundamentals of critical care support through the Society of Critical Care Medicine. Michelle discovered her passion for sepsis care while serving as the Intensivist Program Coordinator for Aultman Hospital from 2002-2009. She is currently employed at Summa Health System as the Sepsis Program Coordinator, a program/role created in January, 2021. Michelle resides in Canton, Ohio, with her husband Dave, and Luke, her youngest of three sons.
Devang Sanghavi, MD, MHA, FCCP
Vice Chairman, Clinical Practice and Critical Care
Mayo Clinic, Jacksonville, FL
Devang Sanghavi, MD, MHA, FCCP, is Vice Chairman, Clinical Practice and Critical Care and an Associate Professor at Mayo Clinic in Jacksonville, Florida. His educational experience includes board certification in internal medicine from Presence Saint Joseph Hospital in Chicago and Chief Residency in Internal Medicine at Presence Saint Joseph Hospital. He graduated from the Critical Care fellowship training program at Mayo Clinic, Rochester, followed by board certification in Critical Care Medicine. Dr. Sanghavi completed his graduate training at Washington University School of Medicine in Saint Louis, having completed a two-year master's program in Health Administration.
As a Chief Resident in Chicago, Dr. Sanghavi led a group of eighty-four residents and medical students, which tested his administrative, leadership, and teaching skills. Caring for a critically ill patient with multisystem involvement demands an alert physician, one who is a team player, quick, decisive, and ready to respond to the ever-changing needs of this patient. It is these very demanding conditions and the daily change of medical conditions that one may treat that drew Dr. Sanghavi to critical care.
Alexis Wells, RN, MSN, LSSYB, CCDS
Quality Educator, Outcomes Management & Quality Division
JPS Health Network
Alexis Wells, MSN, RN, LSSYB, CCDS, has been a registered nurse since 2008 working in various areas including CVICU, neuro ICU, med/surg ICU, telemetry, bone marrow transplant unit, and home hospice, which provided a well-rounded foundation when she became a clinical documentation specialist (CDS) in 2015. Within six months, Alexis was promoted as the clinical coordinator at her facility, providing education to providers and cultivating relationships with essential ancillary departments such as dietary, wound care, and IT. In 2018, Alexis was hired at John Peter Smith (JPS) Hospital as the CDI Quality Assurance Auditor, where she continued the same goal to break down barriers and improve workflow and engagement of everyone involved with clinical documentation. In December 2021, Alexis transitioned to a new role at John Peter Smith as the Quality Educator for the entire organization.
Alexis has taken care of multiple patients with sepsis and understands early identification and intervention is KEY to survival, which is why she took to action again when the question was posed: how do you bridge patient care and reimbursement when it comes to the septic population?
Jessica Aguilar, BSN, RN, LP, LSSGB
Sepsis Coordinator
JPS Health Network
Jessica Aguilar, BSN, RN is a clinical sepsis nurse at JPS Health Network in Ft. Worth, Texas. As a clinical sepsis nurse, she is responsible for educating patients and staff on sepsis. She is currently completing her Masters in Nursing Administration at Texas Tech University. She began her career as a pharmacy tech, then obtained her EMT and EMT-Paramedic prior to completing her BSN. She previously worked as a bedside nurse at Cook Children’s Medical Center from 2015-2017 and was involved in hardwiring sepsis rollout to all floors. From 2017-2019 Jessica was an emergency department nurse at JPS Health Network and served as the Chair of the Stroke Committee. Additionally, she was a member of the sepsis, AMI, triage, and MCI committees. Outside of work, Jessica enjoys spending time with her daughter, crafting, working out, and gardening.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 2.3 contact hours.
Other healthcare professionals will receive a certificate of attendance for 1.9 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
-
Recorded On: 06/22/2023
Recorded symposium featuring subject matter experts in precision medicine and sepsis.
Description:
The clinical complexity and heterogeneity following infection and sepsis is a well-recognized challenge to effective patient management. Traditional pathogen-only targeted treatment currently remains the standard of care in diagnosis and treatment. Precision medicine, a concept that has been around for many years, applies host-directed diagnostics and therapeutics to use a person’s own genes or proteins as a potential way to yield more precise diagnoses, predict disease risk before symptoms occur, and design customized treatment plans that maximize safety and efficiency. For the medical community, precision medicine holds a lot of promise and hope for improved, personalized care and outcomes in infectious diseases and sepsis.
This Sepsis Alliance Symposium, focused on precision medicine in sepsis care and examining host-directed diagnosis and treatment for infectious diseases and sepsis, will allow learners to better understand the host response and how precision medicine might be applied. Presenters will also review host-based diagnostics across the continuum and explore the role of data and machine learning in host-based diagnostics and therapeutics.
Learning Objectives:
At the end of the activity, the learner should be able to:
- Identify the immune activation to immune suppression;
- Review current host-directed diagnostics and phenotyping being researched, translated, and used in infection and sepsis care;
- List possible approaches to host-directed therapeutics in infection and sepsis care;
- Describe the role of data and machine learning in precision medicine.
Target Audience:
Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more.
Session 1: Immunotherapy of Sepsis: The Right Patient at the Right Time with the Right Drug
Speaker: Richard Hotchkiss, MD
Description: The evolving nature of sepsis highlights the crucial role of immunotherapy in its management. This session will delve into the transition of sepsis from a hyper-inflammatory phase to a prolonged immunosuppressive phase, shedding light on the underlying mechanisms and implications for patient outcomes. The critical phase in which the majority of sepsis-related deaths occur will be discussed, along with how to prioritize interventions to improve sepsis survival rates. Emerging immune adjuvant therapy options that can enhance patients’ ability to effectively combat invading pathogens, providing potential breakthroughs in sepsis treatment will also be explored. Learners can expect to become equipped with valuable knowledge to identify the right patients, determine optimal timing, and select the appropriate immunotherapy for sepsis management, ultimately improving patient outcomes.
Session Objectives: At the end of this session, the learner should be able to:
- Describe how sepsis can evolve from a hyper-inflammatory phase to a more prolonged immunosuppressive phase;
- Identify the phase in which most deaths in sepsis occur;
- List emerging immune adjuvant therapy options to boost patients’ ability to contain and eliminate invading pathogens.
Session 2: Phenotypes in Pediatric Sepsis and the Importance of Personalized Care
Speaker: L. Nelson Sanchez-Pinto, MD, MBI, FAMIA
Description: Pediatric sepsis is a heterogenous disease: not every child with sepsis has the same type of response to infection or presents with the same clinical picture. These differences can make some children more likely to respond to, or be harmed by, specific therapies. Different children may require very different clinical trajectories. In this presentation, learners will review the importance of identifying and studying phenotypes of pediatric sepsis to advance the science of this potentially devastating syndrome, and how to provide more personalized care to the children affected by it.
Session Objectives: At the end of this session, the learner should be able to:
- Restate the importance of phenotypes and personalized care in pediatric sepsis;
- List some key examples of pediatric sepsis phenotypes described in the literature;
- Describe the concepts of predictive and prognostic enrichment and how they relate to phenotypes and personalized care in pediatric sepsis.
Session 3: Shaping the Future of Sepsis Care: The Role of Phenotyping in Prognosis
Speaker: Azra Bihorac, MD, MS, FCCM, FASN
Description: To use precision medicine for providing sepsis patients with the best available care, we need to understand sepsis subclasses and their biological basis. Current phenotypes of acute kidney injury (AKI), however, are not consistent and are classified by different criteria such as timeline or acuity. Confusion can result from the existing efforts to define sepsis subclasses, where researchers may have used different approaches to classification (empirical, hypothesis-based, or agnostic) and may have used interchangeable terms (such as subgroup, sub-phenotype, or endotype) that were not reconciled with terminology from previously published studies. This presentation will discuss current efforts to establish data-driven phenotypes and how these efforts could be converted into clinical impact in the future.
Session Objectives: At the end of this session, the learner should be able to:
- Discuss and analyze the heterogeneous approaches to defining sepsis phenotypes;
- Examine the challenges of and potential next steps toward making a clinical impact with sepsis phenotypes.
Session 4: A Sepsis Innovation Collaborative (SIC) Roundtable: Challenges and Opportunities in Precision Sepsis Diagnosis
Speakers: Steven Q. Simpson, MD; Tim Sweeney, MD, PhD; Debra M. Foster, BSc; Bobby Reddy Jr., PhD; Vincent Liu, MD, MS
Description: Sepsis Innovation Collaborative (SIC) is a multi-stakeholder collaborative that brings together academic, clinical, industry, patient advocacy, and other stakeholders. This roundtable with SIC members will dive into the common challenges and unmet needs related to sepsis and the opportunities precision medicine provides for addressing these issues. In this roundtable session, panelists will address the latest research, technological breakthroughs, and emerging trends, offering participants a unique opportunity to learn about the ongoing development of precision medicine strategies in sepsis management. Panelists will also share how SIC is working to improve patient outcomes and enhance sepsis diagnosis and management through precision medicine.
Session 5: Human Genomics of Infectious Diseases & Sepsis
Speaker: Samira Asgari, PhD
Description: Understanding how human genetic diversity translates to phenotypic diversity in the immune system and how this phenotypic diversity affects the clinical outcome of infectious diseases is critical for developing better preventative and therapeutic measures to fight infections and sepsis. These human genetic differences may be the key to understanding the interindividual variability for infectious disease outcomes. This presentation will provide an overview of the outcomes of any infection and sepsis and the complex interplay between host, pathogen, and the environment. Future applications of precision medicine and host genetics to help patients and decrease health inequities will also be discussed.
Session Objectives: At the end of this session, the learner should be able to:
- Summarize the spectrum of genetic architectures in diseases;
- Evaluate methods and approaches used to study human genomics of infectious diseases.
Session 6: Strategies for Building a Better Approach to Host-Targeted Therapeutics in Sepsis Care
Speaker: Timothy G. Buchman, Ph.D., M.D., FACS, FCCP, MCCM
Description: The frustration experienced by the healthcare community when encountering situations where two patients with similar characteristics receive identical treatment, but one survives while the other succumbs to multiple organ system failure, is a common sentiment. This discrepancy in outcomes may potentially be attributed to variations in host-response. Understanding the impact of individual host-response to infection is crucial in advancing our knowledge of sepsis and improving personalized patient care.
In this session, host response to infection will be highlighted, along with the dysregulated host responses which characterize sepsis. Lessons and insights learned from the COVID-19 pandemic will be used to provide an in-depth analysis of the current state of host-targeted therapies with steps that can be taken to provide a more personalized approach to sepsis assessment and care.
Session Objectives: At the end of this session, the learner should be able to:
- Describe the host response to infection;
- Identify the dysregulated host responses that characterize sepsis;
- Describe the current state of host-targeted therapies that are widely used, including a review of the COVID-19 experience;
- Recognize the need and promise for personalized assessment and care;
- Explain immediate and intermediate “next steps” to improve the approach to personalized assessment and care.
Session 7: Resuscitation and Management: Knowns, Unknowns, and the Role for Big Data
Speaker: Andre L. Holder, MD, MS
Description: Big data and artificial intelligence (AI) have the potential to improve sepsis care in a number of ways. For example, big data can be used to identify patients at risk for sepsis, to develop personalized treatment plans, and to monitor patient outcomes. AI can be used to develop algorithms that can predict sepsis, to identify patients who are not responding to treatment, and to recommend interventions that are most likely to be successful. This presentation will discuss the current state of knowledge on sepsis resuscitation and management, as well as the areas where there is still uncertainty or controversy. The presentation will also discuss the potential role of big data and artificial intelligence (AI) in improving sepsis care.
Session Objectives: At the end of this session, the learner should be able to:
- Summarize topics in which the Surviving Sepsis Campaign provides insufficient guidance or management is controversial:
- Restate proper fluid resuscitation techniques in patients with heart failure or ESRD;
- Overview timing and patient selection for steroids and other immunosuppressants;
- Outline “pre-clinical” detection of sepsis or its sequelae;
- Restate potential approaches in which Artificial Intelligence (AI) can provide guidance in these three areas.
Steven Q. Simpson, MD (Moderator)
Professor of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine
University of Kansas
Steven Q. Simpson, MD is Professor of Medicine at the University of Kansas in the Division of Pulmonary, Critical Care, and Sleep Medicine, where he previously served as Division Director, Director of three ICUs, Chair of the Sepsis Team, and Chair of Multidisciplinary Critical Care. He has done research in all areas of severe sepsis from molecular and cellular mechanisms, to translational studies, to quality improvement studies.
He was a founder, in 2005, of the Midwest Critical Care Collaborative, a multidisciplinary and interprofessional collaborative effort to improve the quality of critical care services throughout the Midwest. In 2007, he initiated the Kansas Sepsis Project, a statewide program to improve severe sepsis care and outcomes throughout the state via continuing education both in sepsis and in quality improvement principles, and via inter-professional collaboration. He is currently heading a BCBS-sponsored sepsis collaborative among Kansas City metro area hospitals and is a contributing faculty member of the ongoing Surviving Sepsis Campaign collaboratives, leading the effort in the Midwest. He is a participant in the 2016 review and update of the Surviving Sepsis Campaign Guidelines.
Dr. Simpson was the North American co-chair of the International Single Day Point Prevalence Study for Severe Sepsis and Septic Shock (IMPRESS) in the fall of 2013. During his tenure at the University of New Mexico, he contributed to the discovery of a particular form of sepsis, the Hantavirus Pulmonary Syndrome, and published numerous papers on the clinical description, the hemodynamic description, and the approach to supportive care for patients with the syndrome, including extracorporeal hemodynamic and oxygenation support.
Dr. Simpson received his M.D. degree from the University of Kansas in 1983. He completed residency training in Internal Medicine at KU in 1986 and fellowship training in Pulmonary Diseases at Rush Medical College in 1989. He has been a faculty member at Rush Medical College, the University of New Mexico, and the University of Kansas. He is a regular reviewer for the journals Critical Care Medicine and CHEST, and he reviews on an ad hoc basis for Shock, the Journal of Intensive Care, JAMA, Virology, and Antiviral Therapy. He is the author of over 70 peer reviewed and invited manuscripts, book chapters, and web-based articles and presentations.
Dr. Simpson was the Third Eli Lilly and Company Distinguished Scholar in Critical Care Medicine, sponsored by the American College of Chest Physicians and the Chest Foundation for his work in reducing geographic disparities for severe sepsis care (the Kansas Sepsis Project). In 2013 he delivered the Roger C. Bone Memorial Lecture at the annual international meeting of the American College of Chest Physicians, describing the Kansas Sepsis Project. Dr. Bone was Dr. Simpson’s early career mentor and was the progenitor of the criteria used throughout the world to recognize severe sepsis.
No relevant financial relationships to disclose.
Richard Hotchkiss, MD
Professor of Anesthesiology, Medicine, Surgery, and Developmental Biology
Washington University School of Medicine
Richard Hotchkiss, MD, studied at the University of Virginia where he received both his undergraduate and medical degrees and was inducted into the Phi Beta Kappa and Alpha Omega Alpha Honor Societies. He trained in two specialties, first in Internal Medicine at Emory University School of Medicine (where he was also Chief Resident), and then in Anesthesia at the Massachusetts General Hospital. Dr. Hotchkiss pursued his interest in critical care as a Fellow at the University of Virginia and then as a Senior Fellow in the Respiratory Intensive Care Unit. In 1987, Dr. Hotchkiss moved to the Department of Anesthesiology at Washington University in St. Louis where he has remained, climbing the ranks to Professor in the Departments of Anesthesiology, Medicine, Surgery, and Molecular Biology & Pharmacology.
Dr. Hotchkiss has had a long, successful career as an investigator studying the pathophysiology of sepsis. His many contributions are documented in over 200 publications. A seminal observation from his laboratory was the identification of extensive apoptotic death of immune effector cells in patients dying of sepsis. This discovery led to the concept that apoptosis-induced immunosuppression is an important pathogenic mechanism in sepsis, a finding that has changed the paradigm in search of new therapeutic approaches to this major threat to public health. A review article on sepsis by Drs. Hotchkiss and Irene Karl helped define and promulgate this concept and is now the sixth most cited review article in the New England Journal of Medicine in the last decade.
Dr. Hotchkiss has been continuously funded by the National Institutes of Health for approximately 20 years and is the recipient of a number of prestigious awards, including the NIH Research Career Development Award (1995) and the NIGMS Merit Award (2003). Additional honors include serving as President of the Shock Society for which he received the Distinguished Service Award of the Society in 2007. Washington University in St. Louis honored him with its Distinguished Investigator Award in 2008.
Lazaro Nelson Sanchez-Pinto, MD, MBI
Assistant Professor of Pediatrics (Critical Care)
Northwestern University Feinberg School of Medicine
Nelson Sanchez-Pinto is an Assistant Professor of Pediatrics at Northwestern University Feinberg School of Medicine, biomedical informatics specialist, and clinical data scientist. His clinical and academic interests focus on patients with a host of critical conditions, including sepsis.
Azra Bihorac, MD, MS, FCCM, FASN
Senior Associate Dean for Research
University of Florida College of Medicine
Azra Bihorac, MD, MS, FCCM, FASN, is the Senior Associate Dean for Research at the University of Florida College of Medicine. She is the R. Glenn Davis Professor of Medicine, Surgery, Anesthesiology, and Physiology and Functional Genomics; the Lab Director of the Precision and Intelligent Systems in Medicine Research Partnership (PRISMA); and Co-Director of the Intelligent Critical Care Center (IC), a multi-disciplinary center focused on providing sustainable support and leadership for transformative medical AI research, education, and clinical applications to advance patients’ health in critical and acute care medicine.
Through her research, Dr. Bihorac is addressing an unprecedented opportunity for world-leading ambient, immersive, and AI innovation to transform the diagnosis, monitoring, and treatment for critically and acutely ill patients. Dr. Bihorac’s vision is to develop tools for intelligent human-centered health care that is tailored to a patient’s “personal clinical profile” using digital data. She is a nationally and internationally recognized expert in medical AI, data science, informatics, and translational research. Since 2010, she has had continuous NIH funding and 185 peer-reviewed publications with more than 10,000 citations.
Dr. Bihorac is currently a PI for multiple NIH-funded programs, including a $23.5 million, multicenter Bridge2AI project called “A Patient-Focused CHoRUS for Equitable AI,” which seeks to develop a 100,000-patient dataset for AI research in critical care along with AI workforce training events and a set of standards for the ethical use of AI in critical care.
Tim Sweeney, MD, PhD
Co-Founder and Chief Executive Officer
Inflammatix
Tim Sweeney, MD, PhD, helped invent the core Inflammatix technology and is a licensed physician and data scientist. He completed his MD/PhD at Duke University and then spent time training in the general surgery residency program at Stanford University. While training as a surgeon, he became frustrated with the current diagnostic tools for infection. During his residency research years, he completed a postdoc MS in Biomedical Informatics, during which he worked with Dr. Khatri to identify a new way to diagnose infections based on ‘reading’ the immune system. Their work designing custom informatics algorithms for sifting through heterogeneous large datasets led to the core technology on which Inflammatix is based.
Debra Foster, BSc
Clinical Consultant
Spectral Medical
Debra Foster, BSc, began her professional career as a registered nurse, specializing in the adult critical care area. Shortly thereafter, Debra joined the critical care clinical research team at Toronto General Hospital. While there, Debra was the project lead for a multi-national, multi-center clinical trial, the MEDIC study. The data was used for a successful 510k de novo submission to the FDA for the Endotoxin Activity Assay (EAA). It was the first in vitro disagnostic (IVD) in the field of sepsis. Debra followed the device to its commercial partner, becoming an employee of Spectral Medical. She was appointed Vice President of Clinical Development in 2011. Debra has led many clinical research projects, including the EUPHRATES and TIGRIS clinical trials for a device to treat patients with endotoxemic septic shock. In December 2021, Debra opted for partial retirement and remains a clinical consultant for Spectral Medical.
Debra has lectured many times to medical professionals on the topics of sepsis and clinical trials for sepsis. She has co-authored more than 50 articles in peer-reviewed journals and lectured for academic and industry audiences.
Session Title: Spectral Medical Sponsored Session: What is Endotoxin and Why is it Important?
Session Day/Time: Wednesday, September 27, 2023, 1:40 - 2:10 PM EST
Bobby Reddy Jr., PhD
CEO & Co-Founder
Prenosis
Bobby Reddy, Jr., Ph.D., is an engineer turned entrepreneur who has focused on the development and commercialization of precision medicine products for over 14 years. He co-founded Prenosis, Inc. in 2014 and serves as its CEO. In this role, he has raised capital from investors, been awarded numerous research grants, recruited a dynamic and multi-disciplinary team, and executed various strategic partnerships with huge diagnostic companies, hospitals, manufacturers, technology partners, and others. He is passionate about the problem of the deconvoluting heterogeneity of immune system dysregulation and its relevance in sepsis and other diseases. Dr. Reddy received his Ph.D. in electrical engineering from University of Illinois Urbana-Champaign (UIUC) in 2012 with a focus on biotech devices and algorithms.
Vincent Liu, MD, MS
Research Scientist
Kaiser Permanente Division of Research
Vincent Liu, MD, MS, is a research scientist at the Kaiser Permanente Northern California Division of Research. His work focuses on the intersection of sepsis, acute severe illness, informatics, and health care delivery with a goal of building a learning hospital system. Dr. Liu is board certified in Internal Medicine, Pulmonary Disease, Critical Care Medicine, and Clinical Informatics. He received his undergraduate degree from the University of Pennsylvania and his medical degree from New York University. He completed his residency training at New York University Hospitals (Bellevue) and a chief residency at Memorial Sloan-Kettering Cancer Center. He also completed a pulmonary and critical care medicine fellowship and has masters degrees in Health Services Research and Biomedical Informatics, both from Stanford University. In addition to his clinical practice and research, Dr. Liu is also the Regional Director of Hospital Advanced Analytics at Kaiser Permanente Northern California, a role in which he leads the development, implementation, deployment, and evaluation of real-time EHR-based risk prediction models across Kaiser Permanente’s 21 hospitals.
Samira Asgari, PhD
Assistant Professor, Institute for Genomic Health, Department of Genetics and Genomic Sciences
Icahn School of Medicine at Mount Sinai
Samira Asgari, Ph.D. was born and raised in Iran. She obtained her Ph.D. in human genomics of infectious disease from École Polytechnique Fédérale de Lausanne (EPFL) in 2012. In 2017, she moved to Boston for her postdoctoral training in human statistical and population genomics at the Brigham and Women’s Hospital. She started her research group at Icahn School of medicine at Mount Sinai in New York City in 2022. Her research focuses on understanding the human genetic basis of infection and immunity. Some of the questions the Dr. Asgari lab asks include:
- What are the human genetic variants underlying susceptibility and resistance to specific pathogens?
- What are the molecular mechanisms connecting these variants to cellular functions and immune responses? and
- How do differences in population history and demography play into susceptibility and resistance to specific pathogens?
To answer these questions, they use a combination of statistical, functional, and population genomics methods.
Timothy G. Buchman PhD, MD, FACS, FCCP, MCCM
Professor of Surgery, Professor of Anesthesiology, Professor of Biomedical Informatics
Emory University School of Medicine
Timothy G. Buchman, PhD, MD, FACS, FCCP, MCCM has four decades of bedside experience caring for septic patients. A general surgeon, intensive care doctor and virologist, he is currently Senior Advisor, IPA to the Division of Research, Innovation, and Ventures (DRIVe), Biomedical Advanced Research and Development Authority (BARDA), Office of Assistant Secretary for Preparedness and Response (ASPR), US Department of Health and Human Services (HHS). Dr. Buchman’s other current roles include Professor of Surgery, Anesthesiology, and Biomedical Informatics at Emory University, where he founded the Emory Critical Care Center. Dr. Buchman is past president of the Shock Society, of the Society for Complex Acute Illness and of the Society of Critical Care Medicine, the latter being the largest organization of critical care professionals in the world. He is Editor-in-Chief of Critical Care Medicine (www.ccmjournal.org) and Critical Care Explorations (www.ccejournal.org). He is a member of the External Faculty of the Santa Fe Institute. He also serves as site director of the military-civilian partnership, Surgical Critical Care Institute (www.sc2i.org).
No financial relationships to disclose.
Andre Holder, MD, MSc
Assistant Professor, Division of Pulmonary Allergy, Critical Care, & Sleep Medicine
Emory University School of Medicine
Dr. Holder is an NIH-funded clinician scientist with board certification in emergency medicine, internal medicine and critical care medicine. He is an assistant professor in the Division of Pulmonary, Allergy, Critical Care and Sleep Medicine at Emory University. His primary area of research focus is the appropriate timing and use of interventions to prevent or mitigate syndromes of critical illness (e.g. sepsis) by forecasting the evolution of patient decompensation and organ failure. Through collaborations with colleagues in Emory’s Department of Biomedical Informatics, he creates and tests data-driven, machine learning algorithms to predict clinical decompensation from sepsis. Other areas of research interest include early sepsis resuscitation and hemodynamic monitoring, cardiopulmonary resuscitation, & novel sepsis biomarkers. He is a practicing intensivist in the medical ICU at Grady Memorial Hospital and the medical/surgical ICU at Emory Midtown Hospital, both in Atlanta, GA.
Provider approved by the California Board of Registered Nursing, Provider Number CEP17068 for 3.6 contact hours.
Other healthcare professionals will receive a certificate of attendance for 3.0 contact hours.
Medical Disclaimer
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare professional. Sepsis Alliance recommends users consult their physician or healthcare professional regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.
-
Recorded On: 06/21/2023
Content provided by bioMérieux (No CE credits offered)
Webinar Description:
Sponsored by bioMérieux.
Joint Infections, including septic arthritis and prosthetic joint infections, can be difficult to diagnose. A delay in treatment can result in permanent morbidity or even mortality. In this webinar, Stephen Vella, PhD, will discuss the challenges of current diagnostics of joint infections and how a new FDA-cleared syndromic PCR panel can guide the diagnosis and treatment of both septic arthritis and prosthetic joint infections. Dr. Vella will review the considerations for use in current diagnostic algorithms, followed by an overview of recent clinical publications. He will share expert recommendations on using the panel to potentially positively impact patient management.
No CE credits are offered for this sponsored webinar. Content was determined by the sponsor.
Webinar Sponsor:
Sepsis Alliance gratefully acknowledges the support provided by bioMérieux for this sponsored webinar.
Stephen Vella, PhD
Medical Science Liaison
bioMérieux
Stephen Vella, PhD, is located outside of Washington DC. Dr. Vella obtained his PhD in Microbiology from the University of Georgia and his undergraduate degree, also in Microbiology, at Indiana University. Currently, Dr. Vella works as a Medical Science Liaison for bioMérieux, specializing in molecular biology. He serves as the U.S.-lead for Joint Infection and is in a supportive role for the Gastrointestinal Panel.